Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Current Assets (2020 - 2026)

Edgewise Therapeutics has reported Current Assets over the past 7 years, most recently at $509.8 million for Q1 2026.

  • Quarterly results put Current Assets at $509.8 million for Q1 2026, up 15.03% from a year ago — trailing twelve months through Mar 2026 was $509.8 million (up 15.03% YoY), and the annual figure for FY2025 was $543.4 million, up 14.28%.
  • Current Assets reached $509.8 million in Q1 2026 per EWTX's latest filing, down from $543.4 million in the prior quarter.
  • Across five years, Current Assets topped out at $603.3 million in Q2 2025 and bottomed at $253.3 million in Q2 2022.
  • Median Current Assets over the past 5 years was $443.2 million (2025), compared with a mean of $425.5 million.
  • The largest annual shift saw Current Assets fell 19.51% in 2023 before it skyrocketed 67.64% in 2024.
  • Over 5 years, Current Assets stood at $357.0 million in 2022, then dropped by 8.4% to $327.0 million in 2023, then soared by 45.41% to $475.5 million in 2024, then grew by 14.28% to $543.4 million in 2025, then decreased by 6.18% to $509.8 million in 2026.
  • Business Quant data shows Current Assets for EWTX at $509.8 million in Q1 2026, $543.4 million in Q4 2025, and $573.9 million in Q3 2025.